myspace.com (Free subscription) | 20/08/2008
Sharath Hegde, Vice President of Pharmacology at Theravance, Inc. in South San Francisco, CA will speak on "Telavancin: A Novel Lipoglycopeptide Gram 1 Vote(s)
Seeking Alpha (Free subscription) | 11/08/2008
Theravance, Inc. (THRX) Q2 2008 Earnings Call Transcript Complete Story »
Red Orbit (Free subscription) | 25/07/2008
Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended June 30, 2008. Net loss for the second quarter of 2008 was $27.0 million, compared with $45.1 million for the same period of 2007, a decrease of $18.1 million.
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 24/07/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended June 30, 2008. Net loss for the second quarter of 2008 was $27.0 million, compared with $45.1 million for the same period of 2007, a decrease of $18.1 million. Net loss per share was $0.44 for the second quarter 2008 compared with a net loss per share of $0.75 for the second...
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 22/07/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that the U.S. Food and Drug Administration (FDA) has not yet made a decision regarding the New Drug Application (NDA) for telavancin. The Prescription Drug User Fee Act (PDUFA) date for action by FDA was July 21, 2008, and as of that date, the company had not received an action letter from the FDA. Telavancin is a...
YHOO - BloggingStocks (Free subscription) | 18/07/2008
Filed under: Earnings reports , Conventions and conferences , Annual meetings , Yahoo! (YHOO) , Apple Inc (AAPL) , Caterpillar (CAT) , Bank of America (BAC) , Merck and Co (MRK) , Lockheed Martin (LMT) , Texas Instruments (TXN) Monday, July 21 Theravance, Inc. (NASDAQ: THRX )'s PDUFA date for Telavancin for the treatment of complicated skin infections. Merck & Co., Inc. (NYSE: MRK ) to report Q2 earnings;...
Red Orbit (Free subscription) | 15/07/2008
Theravance has announced the positive results from a Phase I study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist, GSK1160724/TD-4208, for the treatment of chronic obstructive pulmonary disease.
Fiercebiotech (Free subscription) | 15/07/2008
Mid-stage data from an experimental COPD therapy under development by GlaxoSmithKline researchers came in positive, and that will be worth a $10 million milestone payment for Theravance. Theravance discovered GSK961081 (081), which researchers say was well tolerated in the study with no serious side effects. "We are very encouraged by the results of this study," said Rick Winningham, CEO of Theravance....
Medical News Today (Free subscription) | 15/07/2008
Theravance, Inc. (NASDAQ: THRX) announced the positive results from a Phase 2 study of the lead investigational compound GSK961081 ('081) in the inhaled bifunctional muscarinic antagonist-beta2 agonist (MABA) program. The MABA program was licensed to GlaxoSmithKline (GSK) in 2005 under the terms of the companies' Strategic Alliance Agreement as a potential treatment for patients with chronic obstructive...
Red Orbit (Free subscription) | 15/07/2008
TD-4208 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory diseases such as COPD and asthma. Inhaled muscarinic antagonists are frequently used as bronchodilators for COPD and work by inhibiting muscarinic receptors in the airways, which leads...
Red Orbit (Free subscription) | 29/05/2008
SOUTH SAN FRANCISCO, Calif., May 28, 2008 (PRIME NEWSWIRE) -- Theravance, Inc.
PR News Wire (Free subscription) | 28/05/2008
Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of Increased Diagnosis Rates, According to a New Report from Decision Resources WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of emerging therapies, especially the long-acting beta2 agonist/inhaled...
Red Orbit (Free subscription) | 21/05/2008
WALTHAM, Mass., May 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel glycopeptides such as Pfizer's dalbavancin, Theravance/Astellas's telavancin and Targanta's oritavancin and cephalosporins such as Johnson & Johnson/Basilea's ceftobiprole and Forest Laboratories' ceftaroline will drive the hospital-acquired...
GuruFocus Updates (Free subscription) | 15/05/2008
Renowned value investor Seth Klarman must know something others donâ??t. An used copy of his book â??Margin of Safetyâ? is selling for more than $800. It is hard for followers to understand his research. These are his buys and sells during the first quarter.
GuruFocus Updates (Free subscription) | 15/05/2008
Seth Klarman initiated holdings in Pharmaceuticals company Theravance Inc. (THRX) during the 3-months ended 2008-03-31. His purchase prices were between $ 9.4 and $ 22.18, with an estimated average price of $ 16.3. The impact to his portfolio due to this purchase was 3.41 %. His holdings was 5328598 shares as of 2008-03-31. As of last market close, the price of Theravance Inc. (THRX) was $ 12.62.
